NTRK Fusion in Non-Small Cell Lung Cancer: Diagnosis, Therapy, and TRK Inhibitor Resistance
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
NTRK Fusion in Non-Small Cell Lung Cancer: Diagnosis, Therapy, and TRK Inhibitor Resistance
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-03-17
DOI
10.3389/fonc.2022.864666
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer Statistics, 2021
- (2021) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
- (2021) Hayato Mizuta et al. Nature Communications
- Quality of Life in Adult and Pediatric Patients with Tropomyosin Receptor Kinase Fusion Cancer Receiving Larotrectinib
- (2021) Shivaani Kummar et al. CURRENT PROBLEMS IN CANCER
- ABCB1 and ABCG2 Restrict Brain and Testis Accumulation and, Alongside CYP3A, Limit Oral Availability of the Novel TRK Inhibitor Selitrectinib
- (2021) Wenlong Li et al. MOLECULAR CANCER THERAPEUTICS
- A novel NCOR2-NTRK1 fusion detected in a patient of lung adenocarcinoma and response to larotrectinib: a case report
- (2021) Lei Zhang et al. BMC Pulmonary Medicine
- Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications
- (2021) M.G. Krebs et al. ESMO Open
- Discovery of the Next-Generation Pan-TRK Kinase Inhibitors for the Treatment of Cancer
- (2021) Zongliang Liu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Liquid biopsy as an option for predictive testing and prognosis in patients with lung cancer
- (2021) Alvida Qvick et al. MOLECULAR MEDICINE
- Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population
- (2021) C. B. Westphalen et al. npj Precision Oncology
- Mechanisms of targeted therapy resistance in a pediatric glioma driven by ETV6-NTRK3 fusion
- (2021) Clare Keddy et al. Cold Spring Harbor Molecular Case Studies
- Discovery of Next-Generation Tropomyosin Receptor Kinase Inhibitors for Combating Multiple Resistance Associated with Protein Mutation
- (2021) Lin-Sheng Zhuo et al. JOURNAL OF MEDICINAL CHEMISTRY
- Evaluating Targeted Next-Generation Sequencing Assays and Reference Materials for NTRK Fusion Detection
- (2021) Christina Bormann Chung et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Molecular Characteristics of Repotrectinib That Enable Potent Inhibition of TRK Fusion Proteins and Resistant Mutations
- (2021) Brion W. Murray et al. MOLECULAR CANCER THERAPEUTICS
- ABCB1 and ABCG2 Control Brain Accumulation and Intestinal Disposition of the Novel ROS1/TRK/ALK Inhibitor Repotrectinib, While OATP1A/1B, ABCG2, and CYP3A Limit Its Oral Availability
- (2021) Wenlong Li et al. Pharmaceutics
- Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
- (2020) David S Hong et al. LANCET ONCOLOGY
- Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front–Mutant ROS1-Rearranged Non–Small Cell Lung Cancer
- (2020) Mi Ran Yun et al. CLINICAL CANCER RESEARCH
- Bioanalytical assay for the new-generation ROS1/TRK/ALK inhibitor repotrectinib in mouse plasma and tissue homogenate using liquid chromatography-tandem mass spectrometry
- (2020) Wenlong Li et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoprotein
- (2020) Holger Fischer et al. NEURO-ONCOLOGY
- Antitumor Activity of Larotrectinib in Esophageal Carcinoma with NTRK Gene Amplification
- (2020) Dirk Hempel et al. ONCOLOGIST
- U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors
- (2020) Kyriakos P. Papadopoulos et al. CLINICAL CANCER RESEARCH
- Inhibition of MEK1/2 Forestalls the Onset of Acquired Resistance to Entrectinib in Multiple Models of NTRK1-Driven Cancer
- (2020) Aria Vaishnavi et al. Cell Reports
- Larotrectinib followed by selitrectinib in a novel DCTN1–NTRK1 fusion undifferentiated pleomorphic sarcoma
- (2020) Xue Na Goh et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- FDA Approval Summary: Entrectinib for the treatment of NTRK-gene fusion solid tumors
- (2020) Leigh Marcus et al. CLINICAL CANCER RESEARCH
- TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors
- (2020) Emiliano Cocco et al. Cancer Discovery
- Genomic characteristics of driver genes in Chinese patients with non‐small cell lung cancer
- (2020) Xiaoyan Si et al. Thoracic Cancer
- Emerging oncogenic fusions other than ALK, ROS1, RET, and NTRK in NSCLC and the role of fusions as resistance mechanisms to targeted therapy
- (2020) Kenichi Suda et al. Translational Lung Cancer Research
- NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors
- (2020) Romel Somwar et al. Communications Biology
- Potential Unreliability of Uncommon ALK, ROS1, and RET Genomic Breakpoints in Predicting the Efficacy of Targeted Therapy in NSCLC
- (2020) Weihua Li et al. Journal of Thoracic Oncology
- Larotrectinib in adult patients with solid tumours: a multicentre, open-label, phase I dose-escalation study
- (2019) D S Hong et al. ANNALS OF ONCOLOGY
- Colorectal carcinomas containing hypermethylated MLH1 promoter and wild type BRAF/KRAS are enriched for targetable kinase fusions
- (2019) Emiliano Cocco et al. CANCER RESEARCH
- Durable clinical response to crizotinib in IRF2BP2-NRTK1 non-small cell lung cancer
- (2019) Buhai Wang et al. Clinical Lung Cancer
- Larotrectinib: First Global Approval
- (2019) Lesley J. Scott DRUGS
- Prevalence of recurrent oncogenic fusion in mismatch repair-deficient colorectal carcinoma with hypermethylated MLH1 and wild-type BRAF and KRAS
- (2019) Jing Wang et al. MODERN PATHOLOGY
- High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no driver alteration detected by DNA sequencing and low tumor mutation burden
- (2019) Ryma Benayed et al. CLINICAL CANCER RESEARCH
- Bioanalytical assay for the novel TRK inhibitor selitrectinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry
- (2019) Rolf W. Sparidans et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- Testing algorithm for identification of patients with TRK fusion cancer
- (2019) Frédérique Penault-Llorca et al. JOURNAL OF CLINICAL PATHOLOGY
- Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from TRK Inhibitor Therapy
- (2019) Susan J. Hsiao et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research
- (2019) C Marchiò et al. ANNALS OF ONCOLOGY
- Entrectinib: First Global Approval
- (2019) Zaina T. Al-Salama et al. DRUGS
- Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy
- (2019) Pengfei Zhao et al. Journal of Hematology & Oncology
- Evidence of NTRK1 fusions as resistance mechanism to EGFR TKI in EGFR+ NSCLC. Results from a large-scale survey of NTRK1 fusions in Chinese lung cancer patients
- (2019) Hui Xia et al. Clinical Lung Cancer
- NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls
- (2019) James P. Solomon et al. MODERN PATHOLOGY
- Resistance to TRK inhibition mediated by convergent MAPK pathway activation
- (2019) Emiliano Cocco et al. NATURE MEDICINE
- Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion
- (2019) E M O’Reilly et al. ANNALS OF ONCOLOGY
- Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer
- (2019) A Amatu et al. ANNALS OF ONCOLOGY
- The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models
- (2019) Ryohei Katayama et al. Nature Communications
- TRK Fusions are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations
- (2019) Ezra Y Rosen et al. CLINICAL CANCER RESEARCH
- Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
- (2019) Robert C Doebele et al. LANCET ONCOLOGY
- Pan-Trk Immunohistochemistry Identifies NTRK Rearrangements in Pediatric Mesenchymal Tumors
- (2018) Erin R. Rudzinski et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Foretinib Overcomes Entrectinib Resistance Associated with theNTRK1G667C Mutation inNTRK1Fusion–Positive Tumor Cells in a Brain Metastasis Model
- (2018) Akihiro Nishiyama et al. CLINICAL CANCER RESEARCH
- Evaluation of pan-TRK immunohistochemistry in infantile fibrosarcoma, lipofibromatosis-like neural tumour and histological mimics
- (2018) Yin P Hung et al. HISTOPATHOLOGY
- Receptor Tyrosine Kinase fusions and BRAF kinase fusions are rare but actionable resistance mechanisms to EGFR tyrosine kinase inhibitors
- (2018) Alexa B. Schrock et al. Journal of Thoracic Oncology
- Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study
- (2018) Theodore W Laetsch et al. LANCET ONCOLOGY
- The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC)
- (2018) Brandon Golding et al. Molecular Cancer
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
- (2018) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and pharmacokinetics of DS-6051b in Japanese patients with non-small cell lung cancer harboring ROS1 fusions: a phase I study
- (2018) Yutaka Fujiwara et al. Oncotarget
- Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR Inhibitor
- (2018) Elena Helman et al. Clinical Lung Cancer
- Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies
- (2018) Justin Taylor et al. JOURNAL OF CLINICAL INVESTIGATION
- Molecular characterization of cancers with NTRK gene fusions
- (2018) Zoran Gatalica et al. MODERN PATHOLOGY
- Validation of the Oncomine™ focus panel for next-generation sequencing of clinical tumour samples
- (2018) Hannah L. Williams et al. VIRCHOWS ARCHIV
- Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations
- (2018) Alexander Drilon et al. Cancer Discovery
- Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion.
- (2018) Zofia Piotrowska et al. Cancer Discovery
- Comprehensive genomic profiling identifies novel NTRK fusions in neuroendocrine tumors
- (2018) Darren S. Sigal et al. Oncotarget
- Recent Advances in Targeting ROS1 in Lung Cancer
- (2017) Jessica J. Lin et al. Journal of Thoracic Oncology
- Recurrent EML4–NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy
- (2017) Alanna J Church et al. MODERN PATHOLOGY
- Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
- (2017) Ahmet Zehir et al. NATURE MEDICINE
- Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance
- (2017) Alison M. Schram et al. Nature Reviews Clinical Oncology
- A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion–Positive Solid Tumors
- (2017) Alexander Drilon et al. Cancer Discovery
- Detecting Gene Rearrangements in Patient Populations Through a 2-Step Diagnostic Test Comprised of Rapid IHC Enrichment Followed by Sensitive Next-Generation Sequencing
- (2017) Danielle A. Murphy et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- Mammary Analogue Secretory Carcinoma of Salivary Glands
- (2016) Alena Skálová et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- What hides behind the MASC: clinical response and acquired resistance to entrectinib afterETV6-NTRK3identification in a mammary analogue secretory carcinoma (MASC)
- (2016) A. Drilon et al. ANNALS OF ONCOLOGY
- New and emerging targeted treatments in advanced non-small-cell lung cancer
- (2016) Fred R Hirsch et al. LANCET
- Secretory Breast Carcinoma
- (2015) Marie Del Castillo et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- ALK Testing in Lung Adenocarcinoma: Technical Aspects to Improve FISH Evaluation in Daily Practice
- (2015) Vittoria Martin et al. Journal of Thoracic Oncology
- Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer
- (2015) Anna F. Farago et al. Journal of Thoracic Oncology
- PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
- (2015) S. P. Patel et al. MOLECULAR CANCER THERAPEUTICS
- Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer
- (2015) M. Russo et al. Cancer Discovery
- An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101
- (2015) R. C. Doebele et al. Cancer Discovery
- Anchored multiplex PCR for targeted next-generation sequencing
- (2014) Zongli Zheng et al. NATURE MEDICINE
- The landscape of kinase fusions in cancer
- (2014) Nicolas Stransky et al. Nature Communications
- TRKing Down an Old Oncogene in a New Era of Targeted Therapy
- (2014) Aria Vaishnavi et al. Cancer Discovery
- Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer
- (2013) Aria Vaishnavi et al. NATURE MEDICINE
- RETFusions Define a Unique Molecular and Clinicopathologic Subtype of Non–Small-Cell Lung Cancer
- (2012) Rui Wang et al. JOURNAL OF CLINICAL ONCOLOGY
- ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
- (2012) Kristin Bergethon et al. JOURNAL OF CLINICAL ONCOLOGY
- Mammary Analog Secretory Carcinoma of Salivary Gland Origin With the ETV6 Gene Rearrangement by FISH
- (2011) Ashton Connor et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Repetitive DNA and next-generation sequencing: computational challenges and solutions
- (2011) Todd J. Treangen et al. NATURE REVIEWS GENETICS
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
- (2009) Alice T. Shaw et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started